Current-label answer
Both branded tirzepatide labels address acute gallbladder disease
The current Eli Lilly Mounjaro and Zepbound prescribing information was updated April 22, 2026. The Mounjaro label says acute gallbladder disease has occurred in clinical trials and calls for gallbladder diagnostic studies and clinical follow-up when cholelithiasis is suspected. The Zepbound label says treatment with Zepbound and GLP-1 receptor agonists is associated with increased occurrence of acute gallbladder disease and calls for gallbladder studies and clinical follow-up when cholecystitis is suspected.
- Mounjaro is labeled for type 2 diabetes in adults and pediatric patients age 10 and older; Peptide12 provides adult care and should not misstate the broader manufacturer label.
- Zepbound is labeled for chronic weight management in specified patients and for moderate to severe obstructive sleep apnea in adults with obesity.
- Gallstones, gallbladder inflammation, biliary colic, and gallbladder removal are related terms, but they are not interchangeable diagnoses and cannot be confirmed by a webpage.
Product-specific evidence
The trial findings should stay tied to the actual branded product and population
In Mounjaro placebo-controlled adult clinical trials, the current label reports acute gallbladder disease—including cholelithiasis, biliary colic, and cholecystectomy—in 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. In pooled Zepbound weight-reduction Studies 1 and 2, the label reports cholelithiasis in 1.1% of treated patients and 1% receiving placebo, cholecystitis in 0.7% and 0.2%, and cholecystectomy in 0.2% and 0%, respectively. The Zepbound label notes that acute gallbladder events were associated with weight reduction and that similar cholelithiasis rates were reported in its weight-reduction and obstructive-sleep-apnea trials.
- These are separate diabetes and weight-management evidence sets, not a head-to-head comparison or one universal tirzepatide gallbladder-risk percentage.
- A small percentage does not make severe symptoms routine, while an event during treatment does not by itself prove what caused it in one patient.
- Branded trial percentages do not establish the incidence, quality, concentration, or safety of a compounded tirzepatide preparation or a research-use product.
Symptoms and differential diagnosis
Upper-abdominal pain needs context rather than a home diagnosis
NIDDK describes gallstone symptoms as sudden pain in the upper right abdomen or the center of the upper abdomen, sometimes lasting several hours, and advises prompt care when pain persists or occurs with nausea or vomiting, fever or chills, jaundice, tea-colored urine, or light-colored stools. Tirzepatide can also overlap with more common gastrointestinal effects, pancreatitis warnings, dehydration, liver or bile-duct conditions, reflux, infection, and unrelated abdominal problems. Pain location or timing alone cannot safely identify the cause.
- Use prompt in-person care for severe or persistent upper-abdominal pain, fever or chills, repeated vomiting, jaundice, dark urine, pale stools, fainting, confusion, inability to keep fluids down, or rapidly worsening symptoms.
- Record the pain location, onset, duration, severity, meal relationship, vomiting, bowel changes, temperature, hydration, urine changes, recent weight change, and every recent treatment or refill change.
- Do not wait for a routine refill visit, take an extra or partial injection, copy a hold or restart plan, or use fasting, detoxes, flushes, enzymes, or supplements to test the diagnosis.
Prior disease and monitoring
Gallbladder history changes the review but does not create one universal answer
Prior gallstones or gallbladder disease are not listed as contraindications in the current Mounjaro or Zepbound labels. That does not establish automatic eligibility or safety. A clinician should review the prior diagnosis, symptoms, imaging, procedures, gallbladder or bile-duct surgery, pancreatitis history, liver history, triglycerides, recent weight change, diabetes medicines, pregnancy plans, current intake, and access to urgent follow-up before starting, continuing, or refilling treatment.
- Bring ultrasound, CT, HIDA, MRCP, emergency, surgical, and laboratory records when available, along with the reason and date for any gallbladder procedure.
- Share insulin, sulfonylureas, other diabetes medicines, diuretics, recent antibiotics or pain medicines, supplements, dehydration episodes, and changes in alcohol use.
- A prior cholecystectomy is a separate clinical question; it does not eliminate every bile-duct, pancreatic, liver, postoperative, or medication risk.
Product and telehealth boundary
Compounded tirzepatide is not FDA-approved Mounjaro or Zepbound
Mounjaro and Zepbound are FDA-approved finished tirzepatide products with manufacturer labels, specific indications, presentations, and clinical programs. A patient-specific compounded tirzepatide preparation is not FDA-approved Mounjaro, Zepbound, or an FDA-approved generic finished product. Concentration, inactive ingredients, container, storage, beyond-use date, and pharmacy instructions can differ. A responsible telehealth service should confirm the actual package or pharmacy label, screen symptoms before refills, and provide a practical in-person escalation pathway.
- Preserve the product name, manufacturer or dispensing pharmacy, indication, strength or concentration, container, lot or refill details, storage history, and a photo of the current label.
- Avoid research-use vials, counterfeit pens, unlabeled syringes, copied unit charts, no-prescription sellers, or claims that an additive prevents gallstones or protects the gallbladder.
- Contact the responsible clinician for product-specific instructions, but use local urgent or emergency care when symptoms cannot safely wait for a portal response.